Expanded Access for IMMU-132

NCT04320693 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Metastatic Triple-Negative Breast Carcinoma

Interventions

DRUG: IMMU-132

Sponsor

Gilead Sciences